{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:14:56Z","timestamp":1773288896798,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s12325-013-0074-8","type":"journal-article","created":{"date-parts":[[2013,11,29]],"date-time":"2013-11-29T02:27:07Z","timestamp":1385692027000},"page":"1128-1140","source":"Crossref","is-referenced-by-count":21,"title":["The INITIATOR Study: Pilot Data on Real-World Clinical and Economic Outcomes in US Patients with Type 2 Diabetes Initiating Injectable Therapy"],"prefix":"10.1007","volume":"30","author":[{"given":"Sarah","family":"Thayer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Buysman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee","family":"Brekke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Crown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Grabner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swetha","family":"Raparla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Quimbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Cziraky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenli","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Cuddihy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,30]]},"reference":[{"key":"74_CR1","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","volume":"35","author":"SE Inzucchi","year":"2012","unstructured":"Inzucchi SE, Nauck M, Bergenstal RM, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care. 2012;35:1364\u201379.","journal-title":"Diabetes Care"},{"key":"74_CR2","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.2337\/diacare.28.11.2673","volume":"28","author":"M Peyrot","year":"2005","unstructured":"Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national diabetes attitudes, wishes, and needs (DAWN) study. Diabetes Care. 2005;28:2673\u20139.","journal-title":"Diabetes Care"},{"key":"74_CR3","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2337\/dc09-1184","volume":"33","author":"AJ Karter","year":"2010","unstructured":"Karter AJ, Subramanian U, Saha C, et al. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care. 2010;33:733\u20135.","journal-title":"Diabetes Care"},{"key":"74_CR4","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1185\/030079907X242638","volume":"23","author":"SA Oliveria","year":"2007","unstructured":"Oliveria SA, Menditto LA, Ulcickas Yood M, Koo YH, Wells KE, McCarthy BD. Barriers to the initiation of, and persistence with, insulin therapy. Curr Med Res Opin. 2007;23:3105\u201312.","journal-title":"Curr Med Res Opin."},{"key":"74_CR5","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1177\/193229681100500633","volume":"5","author":"BJ Anderson","year":"2011","unstructured":"Anderson BJ, Redondo MJ. What can we learn from patient-reported outcomes of insulin pen devices? J Diabetes Sci Technol. 2011;5:1563\u201371.","journal-title":"J Diabetes Sci Technol."},{"key":"74_CR6","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1185\/03007990802278644","volume":"24","author":"M Peyrot","year":"2008","unstructured":"Peyrot M, Rubin RR. Physician perception and recommendation of insulin pens for patients with type 2 diabetes mellitus. Curr Med Res Opin. 2008;24:2413\u201322.","journal-title":"Curr Med Res Opin."},{"key":"74_CR7","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1089\/dia.2009.0180","volume":"12","author":"CV Asche","year":"2010","unstructured":"Asche CV, Shane-McWhorter L, Raparla S. Health economics and compliance of vials\/syringes versus pen devices: a review of the evidence. Diabetes Technol Ther. 2010;12:S101\u20138.","journal-title":"Diabetes Technol Ther"},{"key":"74_CR8","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.clinthera.2006.10.004","volume":"28","author":"W Lee","year":"2006","unstructured":"Lee W, Balu S, Cobden D, Joshi AV, Pashos CL. Medication adherence and the associated health economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third party managed care claims data. Clin Ther. 2006;28:1712\u201323.","journal-title":"Clin Ther"},{"key":"74_CR9","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.clinthera.2007.07.007","volume":"29","author":"MD Pawaskar","year":"2007","unstructured":"Pawaskar MD, Camacho FT, Anderson RT, Cobden D, Joshi AV, Balkrishnan R. Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther. 2007;29:1294\u2013305.","journal-title":"Clin Ther."},{"key":"74_CR10","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","volume":"52","author":"D Russell-Jones","year":"2009","unstructured":"Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met\u00a0+\u00a0SU): a randomised controlled trial. Diabetologia. 2009;52:2046\u201355.","journal-title":"Diabetologia."},{"key":"74_CR11","first-page":"721","volume":"18","author":"HY Chang","year":"2012","unstructured":"Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted diabetes complications severity index in claims data. Am J Manag Care. 2012;18:721\u20136.","journal-title":"Am J Manag Care."},{"key":"74_CR12","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/1062860606288243","volume":"21","author":"LI Solberg","year":"2006","unstructured":"Solberg LI, Engebretson KI, Sperl-Hillen JM, Hroscikoski MC, O\u2019Connor PJ. Are claims data accurate enough to identify patients for performance measures or quality improvement? The case of diabetes, heart disease, and depression. Am J Med Qual. 2006;21:238\u201345.","journal-title":"Am J Med Qual."},{"key":"74_CR13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.diabres.2010.03.007","volume":"89","author":"G Chen","year":"2010","unstructured":"Chen G, Khan N, Walker R, Quan H. Validating ICD coding algorithms for diabetes mellitus from administrative data. Diabetes Res Clin Pract. 2010;89:189\u201395.","journal-title":"Diabetes Res Clin Pract."},{"key":"74_CR14","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130\u20139.","journal-title":"Med Care."},{"key":"74_CR15","unstructured":"US Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Chained Consumer Price Index for all urban consumers (C-CPI-U) 1999-2008, Medical Care. Series ID: SUUR0000SAM. Washington, DC: U.S. Dept. of Labor, Bureau of Labor Statistics, 2008. http:\/\/data.bls.gov\/cgi-bin\/surveymost?su . Last accessed August 28, 2013."},{"key":"74_CR16","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3111\/13696998.2011.605818","volume":"14","author":"O Baser","year":"2011","unstructured":"Baser O, Wei W, Baser E, Xie L. Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID. J Med Econ. 2011;14:673\u201380.","journal-title":"J Med Econ."},{"key":"74_CR17","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1007\/s12325-011-0074-5","volume":"28","author":"L Xie","year":"2011","unstructured":"Xie L, Wei W, Pan C, Du J, Baser O. A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens. Adv Ther. 2011;28:1000\u201311.","journal-title":"Adv Ther."},{"key":"74_CR18","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1089\/dia.2012.0253","volume":"15","author":"L Xie","year":"2013","unstructured":"Xie L, Zhou S, Wei W, Gill J, Pan C, Baser O. Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2013;15:230\u20136.","journal-title":"Diabetes Technol Ther."},{"key":"74_CR19","doi-asserted-by":"crossref","first-page":"845","DOI":"10.4158\/EP10401.OR","volume":"17","author":"SN Davis","year":"2011","unstructured":"Davis SN, Wei W, Garg S. Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting. Endocr Pract. 2011;17:845\u201352.","journal-title":"Endocr Pract."},{"key":"74_CR20","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/dc11-2048","volume":"35","author":"Y Zhao","year":"2012","unstructured":"Zhao Y, Campbell CR, Fonseca V, Shi L. Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes. Diabetes Care. 2012;35:1126\u201332.","journal-title":"Diabetes Care."},{"key":"74_CR21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1463-1326.2011.01493.x","volume":"14","author":"B Zinman","year":"2012","unstructured":"Zinman B, Schmidt WE, Moses A, Lund N, Gough S. Achieving a clinically relevant composite outcome of an HbA1c of\u00a0<\u00a07% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab. 2012;14:77\u201382.","journal-title":"Diabetes Obes Metab."},{"key":"74_CR22","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ijo.2011.158","volume":"36","author":"A Astrup","year":"2012","unstructured":"Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2\u00a0years with the once-daily human GLP-1 analog, liraglutide. Int J Obes. 2012;36:843\u201354.","journal-title":"Int J Obes."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-013-0074-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T23:22:34Z","timestamp":1498087354000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-013-0074-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,30]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["74"],"URL":"https:\/\/doi.org\/10.1007\/s12325-013-0074-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,30]]}}}